The allopurinol metabolite, oxypurinol, drives oligoclonal expansions of drug‐reactive T cells in resolved hypersensitivity cases and drug‐naïve healthy donors
Allergy · 2023
DOI: 10.1111/all.15814 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, 2023. Verfasst von Nicole A Mifsud und 10 weiteren Autor:innen. Beteiligte Einrichtung: Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victor…. Hauptthemen laut MEDLINE: Allopurinol, Stevens-Johnson Syndrome. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Monash University, National Health and Medical Research Council of Australia.
Abstract (Originalsprache)
Allopurinol (ALP) is a successful drug used in the treatment of gout. However, this drug has been implicated in hypersensitivity reactions that can cause severe to life‐threatening reactions such as Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Individuals who carry the human leukocyte antigen (HLA)‐B*58:01 allotype are at higher risk of experiencing a hypersensitivity reaction (odds ratios ranging from 5.62 to 580.3 for mild to severe reactions, respectively). In addition to the parent drug, the metabolite oxypurinol (OXP) is implicated in triggering T cell‐mediated immunopathology via a labile interaction with HLA‐B*58:01. To date, there has been limited information regarding the T‐cell receptor (TCR) repertoire usage of reactive T cells in patients with ALP‐induced SJS or TEN and, in particular, there are no reports examining paired αβTCRs. Here, using in vitro drug‐treated PBMCs isolated from both resolved ALP‐induced SJS/TEN cases and drug‐naïve healthy donors, we show that OXP is the driver of CD8 + T cell‐mediated responses and that drug‐exposed memory T cells can exhibit a proinflammatory immunophenotype similar to T cells described during active disease. Furthermore, this response supported the pharmacological interaction with immune receptors (p‐i) concept by showcasing (i) the labile metabolite interaction with peptide/HLA complexes, (ii) immunogenic complex formation at the cell surface, and (iii) lack of requirement for antigen processing to elicit drug‐induced T cell responsiveness. Examination of paired OXP‐induced αβTCR repertoires highlighted an oligoclonal and private clonotypic profile in both resolved ALP‐induced SJS/TEN cases and drug‐naïve healthy donors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
- Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia.
- Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
- Immunology Division, Department of Microbiology, Department of Microbiology, Chulalongkorn University, Bangkok, Thailand.
- Center of Excellence in Immunology and Immune-mediated Disease, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
ORCID-Profile: Nicole A Mifsud, Patricia T Illing, Johanna E Tuomisto, Heidi Fettke, Kerry A Mullan, James McCluskey, Jamie Rossjohn, Julian Vivian, Anthony W Purcell
Förderung
- Monash University
- National Health and Medical Research Council of Australia
Zitieren
APA
Mifsud, N. A., Illing, P. T., Ho, R., Tuomisto, J. E., Fettke, H., Mullan, K. A., McCluskey, J., Rossjohn, J., Vivian, J., Reantragoon, R., & Purcell, A. W. (2023). The allopurinol metabolite, oxypurinol, drives oligoclonal expansions of drug‐reactive T cells in resolved hypersensitivity cases and drug‐naïve healthy donors. Allergy. https://doi.org/10.1111/all.15814
Vancouver
Mifsud NA, Illing PT, Ho R, Tuomisto JE, Fettke H, Mullan KA, et al. The allopurinol metabolite, oxypurinol, drives oligoclonal expansions of drug‐reactive T cells in resolved hypersensitivity cases and drug‐naïve healthy donors. Allergy. 2023. doi:10.1111/all.15814
BibTeX
@article{Mifsud2023,
author = {Mifsud, Nicole A and Illing, Patricia T and Ho, Rebecca and Tuomisto, Johanna E and Fettke, Heidi and Mullan, Kerry A and McCluskey, James and Rossjohn, Jamie and Vivian, Julian and Reantragoon, Rangsima and Purcell, Anthony W},
title = {The allopurinol metabolite, oxypurinol, drives oligoclonal expansions of drug‐reactive T cells in resolved hypersensitivity cases and drug‐naïve healthy donors},
journal = {Allergy},
year = {2023},
doi = {10.1111/all.15814}
}
EUVIMED